BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Discovery

Sun Pharma and Philogen Sign Exclusive Agreement for NIDLEGY™ Commercialization in Europe, Australia, and New Zealand

Under the terms of the agreement, Sun Pharma will have exclusive rights to commercialise Nidlegy™ for indications of skin cancers in the territories ...

May 31, 2023 | News

Oncodesign and Veritas In Silico Collaborate on mRNA-Targeted Drug Development

The drug discovery of mRNA-targeted small molecules is rapidly gaining attention due to the current difficulty of developing drugs against conventional pro...

May 25, 2023 | News

Avixgen accelerates the progress on new drug pipeline development

DxVx has released development updates on the pipelines of its recently acquired company, Avixgen. DxVx acquired about 63% stake of Avixgen, which is a new ...

May 25, 2023 | News

Antengene's ATG-022 Receives Orphan Drug Designations for Gastric and Pancreatic Cancers

Orphan Drugs, also known as Rare Disease Drugs, refers to pharmaceutical products developed for the prevention, diagnosis, and treatment of rare diseases o...

May 24, 2023 | News

HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics

HitGen will utilize its DNA-encoded library (DEL) technology platform, centered around the design, synthesis and screening of DELs, to identify novel inhib...

May 19, 2023 | News

Fujitsu launches "Biodrug Design Accelerator" platform to accelerate peptide drug discovery research

Fujitsu today announced the commercial debut of its "Biodrug Design Accelerator," a platform to manage research processes for peptide (1) drug discovery, w...

May 18, 2023 | News

Antengene Clears U.S. IND for Phase I Trial of ATG-031 Antibody

- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncolog...

May 18, 2023 | News

Antengene Announces NDA Submission for XPOVIO® in Indonesia

"In just six months, we have submitted NDAs for XPOVIO® in three ASEAN countries, Malaysia, Thailand and Indonesia, supporting...

May 17, 2023 | News

Innovent's IBI351 gets NMPA breakthrough designation for advanced colorectal carcinoma

This BTD for IBI351 was based on the pooled analysis of two ongoing clinical trials (NCT05005234, NCT05497336), which include 54 CRC pa...

May 15, 2023 | News

GenAssist's GEN6050 Base Editing Product Submits Pre-IND Application to FDA

Suzhou GenAssist Therapeutic Co.,Ltd recently announced its pre-IND application of their first base editing product, GEN6050 and the acceptance by the FDA....

May 08, 2023 | News

ABM Initiates Phase I Clinical Trial of MEK Inhibitor for Solid Tumor, Doses First Patient

MEK (mitogen-activated protein kinase kinase), a key kinase of the MAPK pathway, is frequently activated in various cancers, including those with RAS mutat...

May 05, 2023 | News

Formosa Pharmaceuticals and AimMax Therapeutics Submit NDA to US FDA for APP13007 for Post-Operative Pain and Inflammation after Ocular Surgery.

This proprietary homogeneous nanosuspension has a solution-like appearance which offers great comfort to the eyes and enhanced drug penetration into ocular...

May 05, 2023 | News

Revolutionizing Drug Development: IQVIA's David Cameron on the Power of Innovative Trial Designs

Can you tell us about your role as Senior Director & Global Head of Novel Trial Design at IQVIA? The Novel Trial Design initiative at IQ...

May 09, 2023 | News

Toshiba's Heavy Ion Therapy System treats patients at Yonsei University Health System.

Toshiba Energy Systems & Solutions Corporation (hereinafter "Toshiba ESS") is pleased to announce today the commencement of treatment using a heavy ion...

April 30, 2023 | News

Stay Connected